INTRODUCTION
PTEN hamartoma tumor syndromes (PHTS) are a collection of rare clinical syndromes inherited in an autosomal dominant manner and associated with germ-line mutations of the tumor suppressor gene PTEN (OMIM 601728) [Eng, 2000] . The PTEN (phosphate, tensin homologue, deleted on chromosome 10) gene encodes a dual-specificity phosphatase that antagonizes the phosphoinositol-3-kinase (PI3K)/Akt pathway, leading to G1 cellcycle arrest and/or apoptosis and also inhibits cell spreading via the focal adhesion kinase pathway [Sansal and Sellers, 2004] . PHTS encompass Cowden syndrome (CS; OMIM 158350), BannayanRiley-Ruvalcaba syndrome (BRRS; OMIM 153480), and Proteuslike syndrome. Of these three entities, CS, occurring in adulthood, and BRRS, a pediatric syndrome, have many overlapping features (macrocephaly, hamartomas, and thyroid abnormalities). Given the clinical similarities between these disorders, the hypothesis of a common genetic pathogenesis has been validated by detection of an identical PTEN mutation in different members of the same family . Therefore, the difference between the two conditions is the age of presentation. Both are considered allelic. CS is an autosomal dominant disorder characterized by multiple hamartomatous lesions (trichillemmomas, oral papillomas, intestinal polyps), and by an increased risk of breast, thyroid, and endometrium cancers . Clinical diagnostic criteria for CS are shown in Table I . Both simplex and familial cases of CS have been identified. However, most CS cases are isolated [Marsh et al., 1999] . Germ-line PTEN mutations have been associated with the majority of CS cases Marsh et al., 1998 ]. The molecular basis of CS in the remaining cases has yet to be determined. BRRS is a rare congenital syndrome characterized by macrocephaly, multiple hemangiomas, and lipomas (subcutaneous and/or visceral), gastrointestinal hamartomatous polyps, neurologic manifestations (autism or cognitive and motor developmental delay), and hyperpigmented macules on the skin of the shaft and glans penis [Gorlin et al., 1992] . Common features include hypotonia associated with a lipid storage myopathy [DiLiberti et al., 1984] and thyroid abnormalities such as Hashimoto's thyroiditis [Gorlin et al., 1992] . Clinical findings of BRRS are shown in Table II . Most BRRS cases have a family history, and are inherited in an autosomal dominant manner [Zonana et al., 1975] . However, there are sporadic cases that do not belong to classic BRRS pedigrees [Carethers et al., 1998 ]. Germ-line PTEN mutations are reported in over half of the patients with BRRS. In contrast with CS, there are no agreed international criteria for the diagnosis of BRRS. However, after the discovery of the PTEN gene, it became apparent that PTEN mutation testing might facilitate early diagnosis in childhood Mester et al., 2011] . Recently a prospective multicenter study defined clinical criteria useful to decide which pediatric (<18 years) patients to test for PTEN (Table III) [Tan et al., 2011] . However, BRRS is not always associated with germ-line mutations in the PTEN gene [Carethers et al., 1998 ]. Therefore, other molecular mechanisms could have occurred to cause the BRRS cases without germ-line PTEN mutations.
MATERIALS AND METHODS Clinical Report
Patient 1 was a 6 1/2-year-old female, third child of nonconsanguineous healthy parents. After an uncomplicated pregnancy, she was born at 38 weeks gestation by cesarean due to polyhydramnios. Her birth weight was 3,270 g (50th-75th centile), length 51 cm (75th-90th centile), and OFC 36 cm (>97th centile). At 1-month of life, generalized hypotonia was noted, for which physiochynesitherapy was started. Because of development (motor, cognitive, and language) delay, some diagnostic investigations were performed. Neurological examination, electroencephalogram, and cranial Computed Tomography scan did not reveal any brain abnormalities; visual evoked potential (VEP) and auditory brain stem responses to complex sounds (cABRs) were normal too. At 4 years and 10 months of age, she developed a right cervical swelling. Ultrasound study showed a hyperechogenic swelling (4.5 cm Â 3.5 cm) in right supraclavicular region. Thorough investigation with Positron emission tomography (PET) failed to reveal any tumor illness with high metabolic activity in right lateral cervical and thoracic regions. Therefore, the patient underwent excision of right cervical-axillary lesion. Findings from histopathologic examination of this lesion were interpreted as a lipoma. As a result of these clinical and anamnestic features the patient was referred to genetic counseling. At first observation, the patient was 6 1/2-years old. Prominent physical findings included macrocephaly (Fig. 1a,b) , with OFC of 58 cm (>95th centile), and overweight, with a weight of 33.5 kg (>95th centile). Her height was normal. A severe scoliosis was noted, and bilateral pes planus was present too. Examination of patient's parents and siblings didn't reveal physical abnormalities. Because of macrocephaly, psychomotor and cognitive delay, and lipomatosis we decided to study PTEN gene.
Patient 2 was a female of 24 months of age. She was first-born to nonconsanguineous healthy parents. She was born at 41.3 weeks gestation from uneventful pregnancy and spontaneous delivery. Her birth weight was 3,730 g (75th-90th centile), length 51 cm (50th-75th centile), and OFC 36.5 cm (>97th centile). By 8 weeks of age, her OFC at 42 cm was >97th centile. Early cognitive and language milestones were reached normally, but she started to walk at 22 months of age. During this period, she was noticed to have multiple thoraco-abdominal swelling (Fig. 2a,b) , which revealed lipomas after excision. Thus, she was referred to our genetic evaluation at 24 months of age: she weighed 12.5 kg (25th-50th centile), 87 cm tall (50th centile), and her OFC was 51 cm (>97th centile). Physical examination revealed extreme macrocephaly, epicanthus, and three café-aulait macules on her trunk, only one measuring greater than 2.5 cm in diameter. A tonsil papilloma was observed too (Fig. 2c) . Her parents had not macrocephaly. As result of the phenotype we performed PTEN molecular analysis.
RESULTS

PTEN Molecular Analysis
Molecular genetic analysis was performed on genomic DNA extracted from peripheral blood leukocytes. Real-time quantitative multiplex PCR analysis and a sequence analysis of PTEN exons (1, 2, 3, 4, 5, 6, 7, 8, and 9) and promoter region were performed [Zhou et al., 2003] . In patient 1 a de novo heterozygous mutation in exon 8 of PTEN (c.959T>A) was identified at codon 320 leading to premature termination of the protein (p.Leu320X). Based on literature review, germ-line mutation p.Leu320X was already reported in both variants c.959T>A and c.959T>G in patients with Cowden syndrome [Nelen et al., 1999; Eng, 2003] . In patient 2 PTEN mutational analysis showed a de novo heterozygous mutation in exon 7 (c.703G>T) resulting in a premature stop at codon 235 (p.Glu235X). To our knowledge, this mutation has never been reported in BRRS patients.
DISCUSSION
In this paper we report our experience following two patients with BRRS phenotype and germ-line PTEN mutations. Both patients came to our attention for clinical features suggestive of BRRS such as macrocephaly, developmental delay, and subcutaneous lipomatosis. Macrocephaly with normal ventricular size has been the most consistent finding in BRRS in several reviews [MorettiFerreira et al., 1989; Gorlin et al., 1992] . It is noteworthy that macrocephaly is usually present from birth and persists into adulthood [DiLiberti, 1998] . Motor delay or learning difficulties occur in most children diagnosed with BRRS [Gorlin et al., 1992] . However, most specific finding in the PHTS is presence of hamartomatous lesions. In both our patients, the diagnosis of BRRS has not been suspected until lipomas were identified. In Patient 1 we found a de novo heterozygous mutation in exon 8 of PTEN (c.959T>A) previously described in CS, confirming that these diseases are allelic, and suggesting that the phenotype may not be predictable on the basis of molecular analysis. It is therefore expected that no clear phenotype-genotype correlation will be made, and that patients with identical mutations may show different phenotype. In Patient 2 a de novo heterozygous mutation in exon 7 of PTEN has been identified at codon 703 (c.703G>T). This specific mutation has not been previously described in patients with BRRS, but it is likely to be pathogenic because it inactivates PTEN protein expression. The PTEN is a tumor suppressor gene with nine exons, which maps to human chromosome 10q23.31. It is also known as MMAC1 (Mutated in Multiple Advanced Cancers 1) [Steck et al., 1997] and TEP1 (TGF-regulated and Epithelial cellenriched Phosphatase 1) [Li and Sun, 1997] , and it encodes a 403 amino acid protein, which is a dual-specificity phosphatase since it can recognize both protein and phospholipid substrates [Li and Sun, 1997; Myers et al., 1998 ]. Most PTEN protein functions are to cause G1 cell-cycle arrest and/or apoptosis, and to inhibit cell migration [Sansal and Sellers, 2004] . Overall, decreased PTEN protein expression correlates with unregulated cellular proliferation. Somatic PTEN deletions and/or mutations occur with a wide distribution of frequencies in sporadic primary tumors, such as endometrial carcinomas, glioblastoma multiform, prostate cancer, breast cancer, and melanomas [De Vivo et al., 2000] . Germ-line PTEN mutations have been identified in patients suffering from CS [Marsh et al., 1998 ], BRRS [Longy et al., 1998 ], and Proteus-like syndrome . However, two additional disease phenotypes may also be associated with germ-line mutation or deletion of the PTEN gene. Germ-line PTEN mutations have been found in 10-20% of patients with autism spectrum disorder (ASD) and extreme macrocephaly, even without other features of BRRS or CS [Butler et al., 2005] . A germ-line mutation (H61D) has also been reported in a patient with features of VATER association (vertebral, anal, radial, and renal malformations in patients with esophageal atresia or tracheoesophageal fistula), hydrocephalus, and macrocephaly [Reardon et al., 2001 ]. To date, over 100 germ-line PTEN mutations have been found in CS e BRRS [Eng, 2003] . These mutations are distributed along the length of the gene, with the exception of exon 9 (no mutation reported) [Bonneau and Longy, 2000] . Most of the mutations have been found in exon 5, 7, and 8, especially in exon 5, which encodes the N-terminal phosphatase catalytic domain [Marsh et al., 1998 ].
Although the clinical manifestations of PHTS differ significantly, all four syndromes are characterized by aberrant tissue growth likely related to tumor suppressor role of PTEN gene. Genotype-phenotype analyses revealed an association between the presence of PTEN mutation in BRRS and the development of benign tumor of various tissues and organs (lipomas, hemangiomas, thyroid adenoma, gastrointestinal hamartomatous polyps) [Hendriks et al., 2003 ]. However, the most serious consequences of PHTS relate to the increased risk of cancers including breast, thyroid, endometrial, and to a lesser extent, renal. Thus far, an increased risk of malignancy has only been documented in CS [Hendriks et al., 2003] . Cancer risk associated with BRRS is unknown. However, several studies reported the presentation of thyroid nodules and thyroid cancer in young children with PHTS [Ngeow et al., 2011; Smith et al., 2011] . Another report of a malignancy concerned a case of breast cancer in a BRRS patient (the paternal grandmother of the proband died at the age 53 years of breast cancer and endometrial adenocarcinoma) [Longy et al., 1998 ]. Furthermore, genotypephenotype analysis within the BRRS group confirmed that breast cancer and fibroadenomas have been found in patients with BRRS, CS, or patients with overlapping features [Marsh et al., 1999] . Therefore, since BRRS and CS are allelic conditions, it may be warranted to follow patients with BRRS and germ-line PTEN mutation with the same surveillance protocol. However, no guidelines currently exist from this point of view. Recently a prospective international study proposed new recommendations for management of patients with PTEN mutation [Tan et al., 2012] . We advise that all patients with PHTS follow a cancer surveillance strategy and also a specific surveillance for gastrointestinal and vascular complications, as shown in Table IV . In both our patients thyroid ultrasound examination has never shown any tumor illness. The fecal occult-blood testing has been negative too. In Patient 2, the tonsillar mass on the right side became larger and rougher after only 6 months (Fig. 3) ; hence, tonsillectomy should be performed for histopathologic examination.
In conclusion, our finding suggest that molecular testing for PTEN gene mutations in patients with extreme macrocephaly, developmental delay, and hamartomatous lesions, even in the absence of other CS/BRRS related clinical features, should be considered. Clinical management of PHTS patients consists of an early multidisciplinary surveillance program starting from diagnosis. FOBT should be considered for the early detection of intestinal hamartomas, which are not believed to increase the risk for colorectal cancer, but may be associated with complications (intussusception, rectal bleeding). c Surveillance may begin 5 or 10 years before the earliest onset of a specific cancer in the family, but not later than the recommended age cutoff point.
FIG. 3. Patient 2:
The tonsil papilloma became larger and rougher after 6 months.
